Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer

  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: A meta-analysis was performed to examine the benefit/risk ratio for the addition of anti- HER MoAbs to chemotherapy in patients with advanced gastric and gastroesophageal cancer from six randomized phase II/III trials. Materials and Methods: We searched relative trials from Pubmed, EMBASE, Cochrane library databases, China National Knowledge Infrastructure databases, Google Scholar and the NIH ClinicalTrials. Primary outcomes were overall response rate (ORR), progression-free survival (PFS), overall survival (OS). Secondary outcomes were toxicities. All analyses were performed using STATA 12.0. Results: This meta-analysis included six randomized controlled trials (RCTs) with 2, 297 patients and we demonstrated that the anti-HER MoAbs arm did have a positive effect on ORR in the anti-HER MoAbs arm (OR 1.28, 95% CI 1.00-1.64, p=0.01). There was an increasing benefit regarding OS (HR 0.74, 95% CI 0.60-0.88, p<0.05) and PFS (HR 0.72, 95% CI 0.60-0.84, p<0.05) in the anti-HER2 subgroup, but a reduction of OS (HR 1.11, 95% CI 0.87-1.36, p<0.05) and PFS (HR 1.13, 95% CI 0.98 -1.28, P<0.05) in anti-EGFR subgroup. Some grade 3-4 toxicity had a significantly higher incidence in the anti-HER MoAbs arm. There was no significant publication bias for all endpoints. Conclusions: The addition of trstuzumab MoAb to chemotherapy for gastric and gastroesophageal cancer significantly improved outcome of OS and PFS endpoints, while other MoAbs led to no improvement in results. Some adverse events were increased in anti-HER MoAbs arm compared with the control.

Keywords

References

  1. Ajani JA (2006). Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin Pharmacother, 7, 1627-31. https://doi.org/10.1517/14656566.7.12.1627
  2. Ajani JA, Baker J, Pisters PW, et al (2002). CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer, 94, 641-6. https://doi.org/10.1002/cncr.10279
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  5. Butts CA, Bodkin D, Middleman EL, et al (2007). Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 25, 5777-84. https://doi.org/10.1200/JCO.2007.13.0856
  6. Cai Y, Wang JY, Liu H (2013). Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev, 14, 5699-703. https://doi.org/10.7314/APJCP.2013.14.10.5699
  7. Colevas AD, Setser A (2004). The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials.
  8. Crosby T, Hurt CN, Falk S, et al (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol, 14, 627-37. https://doi.org/10.1016/S1470-2045(13)70136-0
  9. Douillard JY, Siena S, Cassidy J, et al (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28, 4697-705. https://doi.org/10.1200/JCO.2009.27.4860
  10. Douillard JY, Siena S, Cassidy J, et al (2010b). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28, 4697-705. https://doi.org/10.1200/JCO.2009.27.4860
  11. Egger M, Davey SG, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  12. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  13. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382, 1021-8. https://doi.org/10.1016/S0140-6736(13)61094-6
  14. Hirono Y, Tsugawa K, Fushida S, et al (1995). Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology, 52, 182-8. https://doi.org/10.1159/000227455
  15. Hoag JB, Azizi A, Doherty TJ, et al (2009). Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res, 28, 113. https://doi.org/10.1186/1756-9966-28-113
  16. Huang S, Armstrong EA, Benavente S, et al (2004). Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res, 64, 5355-62. https://doi.org/10.1158/0008-5472.CAN-04-0562
  17. Ibrahim EM, Abouelkhair KM, Al-Masri OA, et al (2011). Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung, 189, 193-8. https://doi.org/10.1007/s00408-011-9286-3
  18. Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 17, 1-12. https://doi.org/10.1016/0197-2456(95)00134-4
  19. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  20. Lacouture ME, Melosky BL (2007). Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett, 12, 1-5.
  21. Lenz HJ (2006). Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology, 20, 5-13.
  22. Li W, Qin J, Sun YH, et al (2010). Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol, 16, 5621-8. https://doi.org/10.3748/wjg.v16.i44.5621
  23. Li X, Shan BE, Wang J, et al (2013). Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PLoS One, 8, 81897. https://doi.org/10.1371/journal.pone.0081897
  24. Lordick F, Kang YK, Chung HC, et al (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 14, 490-9. https://doi.org/10.1016/S1470-2045(13)70102-5
  25. Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21, 2787-99. https://doi.org/10.1200/JCO.2003.01.504
  26. Moher D, Liberati A, Tetzlaff J, et al (2010). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg, 8, 336-41. https://doi.org/10.1016/j.ijsu.2010.02.007
  27. Nordlinger B, Sorbye H, Glimelius B, et al (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol, 14, 1208-15. https://doi.org/10.1016/S1470-2045(13)70447-9
  28. Olayioye MA, Neve RM, Lane HA, et al (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J, 19, 3159-67. https://doi.org/10.1093/emboj/19.13.3159
  29. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  30. Perez EA, Suman VJ, Davidson NE, et al (2008). Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol, 26, 1231-8. https://doi.org/10.1200/JCO.2007.13.5467
  31. Pozzo C, Barone C, Szanto J, et al (2004). Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin.in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol, 15, 1773-81. https://doi.org/10.1093/annonc/mdh473
  32. Rao S, Starling N, Cunningham D, et al (2010). Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients.with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol, 21, 2213-9. https://doi.org/10.1093/annonc/mdq247
  33. Rosell R, Robinet G, Szczesna A, et al (2008). Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol, 19, 362-9. https://doi.org/10.1093/annonc/mdm474
  34. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20. https://doi.org/10.1056/NEJMoa072252
  35. Sasako M (2003). Principles of surgical treatment for curable gastric cancer. J Clin Oncol, 21, 274s-275s. https://doi.org/10.1200/JCO.2003.09.172
  36. Sawaki A, Ohashi Y, Omuro Y, et al (2012). Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer, 15, 313-22. https://doi.org/10.1007/s10120-011-0118-1
  37. Segaert S, Van Cutsem E (2005). Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 16, 1425-33. https://doi.org/10.1093/annonc/mdi279
  38. Shen L, Xu JM, Feng FY, et al (2013). Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a phase III, multi-center, randomized controlled trial, Chinese subreport. Zhonghua Zhong Liu Za Zhi, 35, 295-300 (in Chinese).
  39. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  40. Tabernero J (2007). The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res, 5, 203-20. https://doi.org/10.1158/1541-7786.MCR-06-0404
  41. Van Cutsem E, Kohne CH, Hitre E, et al (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360, 1408-17. https://doi.org/10.1056/NEJMoa0805019
  42. Waddell T, Chau I, Cunningham D, et al (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol, 14, 481-9. https://doi.org/10.1016/S1470-2045(13)70096-2
  43. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245
  44. Yarden Y, Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2, 127-37. https://doi.org/10.1038/35052073
  45. Ychou M, Boige V, Pignon JP, et al (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol, 29, 1715-21. https://doi.org/10.1200/JCO.2010.33.0597
  46. Yonemura Y, Sugiyama K, Fujimura T, et al (1989). Epidermal growth factor receptor status and S-phase fractions in gastric carcinoma. Oncology-Basel, 46, 158-61. https://doi.org/10.1159/000226706
  47. Zeng C, Zhou H, Wei Y, et al (2014). Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials. Chin Med J, 127, 951-6.
  48. Zhang E, Cao W, Cheng C, et al (2014). A systemic analysis of s-1 regimens for treatment of patients with colon cancer. Asian Pac J Cancer Prev, 15, 2191-4. https://doi.org/10.7314/APJCP.2014.15.5.2191

Cited by

  1. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells vol.21, pp.11, 2014, https://doi.org/10.1038/cgt.2014.55
  2. Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2 vol.22, pp.12, 2015, https://doi.org/10.1038/cgt.2015.41
  3. Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis vol.33, pp.2, 2015, https://doi.org/10.3109/08977194.2015.1010643
  4. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2772-5
  5. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature vol.15, pp.1, 2017, https://doi.org/10.1186/s12957-017-1132-5
  6. The role of antiangiogenic agents in the treatment of gastric cancer vol.96, pp.10, 2017, https://doi.org/10.1097/MD.0000000000006301